UVA radiation augments cytotoxic activity of psoralens in melanoma cells

Abstract Purpose: Melanoma is an aggressive form of skin cancer. The aim of the study was to evaluate the influence of UVA radiation and psoralens: 5-methoxypsoralen (5-MOP) or 8-methoxypsoralen (8-MOP) on melanoma cells viability. Materials and methods: The amelanotic C32 and melanotic COLO829 human melanoma cell lines were exposed to increasing concentrations of psoralens (0.1–100 μM) in the presence or absence of UVA radiation. Cell viability was evaluated by the WST-1 assay. Results: We demonstrated that 8-MOP, in contrast to 5-MOP, has no cytotoxic effect on both melanoma cell lines. Simultaneous exposure of cells to 8-MOP and UVA radiation caused significant cytotoxic response in C32 cells where the EC50 value was estimated to be 131.0 μM (UVA dose: 1.3 J/cm2) and 105.3 μM (UVA dose: 2.6 J/cm2). The cytotoxicity of 5-MOP on both C32 and COLO829 cells was significantly augmented by UVA radiation – the EC50 was estimated to be 22.7 or 7.9 μM (UVA dose: 1.3 J/cm2) and 24.2 or 7.0 μM (UVA dose: 2.6 J/cm2), respectively. Conclusions: The demonstrated high cytotoxic response after simultaneous exposure of melanoma cells to psoralens and UVA radiation in vitro suggests the usefulness of PUVA therapy to treat melanoma in vivo.

[1]  E. Tapavicza,et al.  Photochemistry , 2019, ACS In Focus.

[2]  D. Brash,et al.  Unanticipated role of melanin in causing carcinogenic cyclobutane pyrimidine dimers , 2016, Molecular & cellular oncology.

[3]  R. Halaban,et al.  Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure , 2015, Science.

[4]  E. Panaitescu,et al.  Survival rates of patients with metastatic malignant melanoma , 2014, Journal of medicine and life.

[5]  R. Dellinger,et al.  Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis. , 2014, Journal of photochemistry and photobiology. B, Biology.

[6]  F. Giordano,et al.  Effects of psoralens as anti-tumoral agents in breast cancer cells. , 2014, World journal of clinical oncology.

[7]  M. Rather,et al.  Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down? , 2013, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[8]  D. Wrześniok,et al.  Amikacin, kanamycin and tobramycin binding to melanin in the presence of Ca(2+) and Mg(2+) ions. , 2012, Acta poloniae pharmaceutica.

[9]  A. Beberok,et al.  Interaction between ciprofloxacin and melanin: the effect on proliferation and melanization in melanocytes. , 2011, European journal of pharmacology.

[10]  A. Hauschild,et al.  The Oncologist® Academia–Pharma Intersect: Melanoma , 2022 .

[11]  R. Talamini,et al.  CDKN2A and MC1R analysis in amelanotic and pigmented melanoma , 2009, Melanoma research.

[12]  Paul Meredith,et al.  The physical and chemical properties of eumelanin. , 2006, Pigment cell research.

[13]  A. Machado,et al.  Psoralen analogues: synthesis, inhibitory activity of growth of human tumor cell lines and computational studies. , 2006, European journal of medicinal chemistry.

[14]  L. Chen Chen,et al.  Psoralen derivatives and longwave ultraviolet irradiation are active in vitro against human melanoma cell line. , 2004, Journal of photochemistry and photobiology. B, Biology.

[15]  A. Surazynski,et al.  Melanin potentiates daunorubicin-induced inhibition of collagen biosynthesis in human skin fibroblasts. , 2001, European journal of pharmacology.

[16]  B. Diffey,et al.  Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group , 2000, The British journal of dermatology.

[17]  A. Castrucci,et al.  Psoralen activity and binding sites in melanotic and amelanotic human melanoma cells. , 1999, Pigment cell research.

[18]  F. Gasparro,et al.  Psoralen photobiology and photochemotherapy: 50 years of science and medicine. , 1999, Journal of dermatological science.

[19]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[20]  J. Petros,et al.  Methoxypsoralen phototherapy oftransitional cell carcinoma , 1994 .

[21]  J. Petros,et al.  Methoxypsoralen phototherapy of transitional cell carcinoma. , 1994, Urology.

[22]  B. Liu,et al.  Antitumor activity of psoralen on mucoepidermoid carcinoma cell line MEC-1. , 1992, Chinese medical journal.